Premium
Heart valve calcifications in patients with end‐stage renal disease: Analysis for risk factors
Author(s) -
TARRASS FAISSAL,
BENJELLOUN MERYEM,
ZAMD MOHAMED,
MEDKOURI GHISLAINE,
HACHIM KHADIJA,
BENGHANEM MOHAMED GHARBI,
RAMDANI BENYOUNES
Publication year - 2006
Publication title -
nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 61
eISSN - 1440-1797
pISSN - 1320-5358
DOI - 10.1111/j.1440-1797.2006.00696.x
Subject(s) - medicine , alfacalcidol , vitamin d and neurology , hyperparathyroidism , population , secondary hyperparathyroidism , cardiology , parathyroid hormone , calciphylaxis , endocrinology , gastroenterology , calcium , calcification , osteoporosis , bone mineral , environmental health
SUMMARY: Background: The prevalence of valve calcification (VC) in end‐stage renal disease patients is high and information regarding risk factors is scarce. Our aims were to determine the prevalence of VC in our maintenance haemodialysis (HD) population and to examine some possible aetiologic factors for its occurrence. Methods: We studied 90 patients (47 women) on maintenance HD for more than 12 months. An M‐mode two‐dimensional echocardiogram was carried out to evaluate mitral, aortic VC and ventricular geometry. We calculated mean daily calcium intake for the phosphate intestinal chelaing in the previous year to echocardiogram date and also mean values from previous year of Ca, PO4, Ca × PO4, parathyroid hormone, lipide profile, nutritional and inflammatory marquers. Finally consumption of calcium and alfacalcidol was also noted. Results: Thirty‐six patients (40%) presented with VC. Patients with VC were older and showed higher levels of serum calcium (92.00 ± 7.54 vs 89.27 ± 6.86 mg/L, P = 0.04), phosphorus (69.70 ± 18.33 vs 44.90 ± 12.43 mg/L, P < 0.0001), Ca × P product (6164.97 ± 1797.64 vs 4024.70 ± 1066.40 mg 2 /L 2 , P < 0.0001) and poor ventricular geometry, as compared with patients without VC. Moreover, they required higher doses of alfacalcidol for treating secondary hyperparathyroidism (0.43 ± 0.60 vs 0.11 ± 0.46 µg/day, P < 0.0001). Conclusion: Findings of the present study are consistent with a role of altered calcium and phosphate metabolism in the pathogenesis of VC in HD patients.